EATG » Sitges VII: Hepatitis C Treatment – From the pipeline to real life

Sitges VII: Hepatitis C Treatment – From the pipeline to real life

Treatment activists from Europe (EATG) and the USA, and the representatives of Gilead Sciences, BMS, AbbVie, MSD and Janssen participated to the meeting on ‘Hepatitis C Treatment from the pipeline to real life’, held in Sitges between 3-5 October2014. During the meeting the current state of play in the field of HCV treatment science and access were discussed, covering issues such as:

  • the situation in medicines research
  • access to HCV treatment
  • pricing of medicines
  • transparency in how companies proceed with different countries when setting the price
  • the level and points of involvement of patients in the medicines development process were high on the agenda

Download the report of the meeting in PDF for more details

Share on FacebookTweet about this on TwitterShare on Google+Pin on PinterestShare on LinkedIn
News categories: Hepatitis